CDKN2A and diffuse large B-cell lymphoma: ATRi (AZD6738) and WEE1i (AZD1775) display differential activity in a subpopulation of non-germinal-center-B cell (non-GCB) diffuse large B-cell lymphoma (DLBCL) cell lines characterized by high MYC oncogene expression and cyclin-dependent kinase inhibitor 2A/B (CDNK2A/B) deletion [74].